RE:RE:RE:RE:RE:Beam Therapeutics Phase 1 CAR-T study placed on hold by FDANot sure what flaw you are talking about?
I agree with your " manipulation" theory 100%.
Onc shares are not low because of any failed trial or real issue at all.
however, because of where things are.
for example the recent Goblet results alone, should move Onc SP well into the $12-$15ps range.
has not yet?
because of a well orhastrated team, working to keep the SP down.
To fix that, a new reality needs to be established. Strong results, enough to foster a deal with, Roche, Pfizer, Incyte or any other of the pharma they are working with will mov3 the price & huge.
The analysts covering give a mid range target of $15ps, based on a phase 3 MBc partnership alone.
A buyout or other deals, not even in radar as oF yet....with analysts.